These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187 [TBL] [Abstract][Full Text] [Related]
8. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857 [TBL] [Abstract][Full Text] [Related]
9. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases. Imai E; Imai A Intern Med; 2024 Jul; 63(13):1855-1861. PubMed ID: 37926547 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
11. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831 [TBL] [Abstract][Full Text] [Related]
12. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Akizawa T; Yamaguchi Y; Otsuka T; Reusch M Nephron; 2020; 144(8):372-382. PubMed ID: 32580188 [TBL] [Abstract][Full Text] [Related]
13. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. Xie D; Wang J; Wu X; Li M Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615 [TBL] [Abstract][Full Text] [Related]
14. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106 [TBL] [Abstract][Full Text] [Related]
15. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610 [TBL] [Abstract][Full Text] [Related]
16. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Akizawa T; Ueno M; Shiga T; Reusch M Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449 [TBL] [Abstract][Full Text] [Related]
17. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116 [TBL] [Abstract][Full Text] [Related]
18. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089 [TBL] [Abstract][Full Text] [Related]
19. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S; Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289 [TBL] [Abstract][Full Text] [Related]
20. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Akizawa T; Otsuka T; Reusch M; Ueno M Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]